Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 8/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 0.34 |
| ▸ | CYBB | P04839 | 4/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6136691 | 0.95 | MEN1 (0.33) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL4319052 | 0.76 | PTGS1 (0.47) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL4319057 | 0.76 | PTGS1 (0.47) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL4309973 | 0.73 | MEN1 (0.45) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL4309972 | 0.73 | MEN1 (0.45) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL4309936 | 0.68 | PTGS1 (0.40) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL9565692 | 0.66 | MEN1 (0.48) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL9565691 | 0.66 | MEN1 (0.48) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| Fumaric Acid SCHEMBL4310801 | 0.66 | PTGS1 (0.37) | MEN1ALDH1A1GAAKMT2APTGS1 | |
| SCHEMBL9129357 | 0.65 | SIRT1 (0.57) | MEN1ALDH1A1GAAKMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042511-A1 | Neuronal Nitric oxide synthase inhibitors; use to treat ischemia | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2002-04-11 | — | — | US | claimed |
| US-20020042511-A1 | Neuronal Nitric oxide synthase inhibitors; use to treat ischemia | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042511-A1 | Neuronal Nitric oxide synthase inhibitors; use to treat ischemia | XDH, NOS2, NOS3 | MEN1 4366/4885ALDH1A1 541/4885GAA 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.